Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 493-500 , October 2009

Elevated concentrations of serum ischaemia-modified albumin in PCOS, a novel ischaemia marker of coronary artery disease

  • Suleyman Guven (Dr)

      Affiliations

    • Department of Obstetric and Gynecology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey
    • Corresponding Author InformationCorrespondence:
    • ,
  • S Caner Karahan

      Affiliations

    • Department of Biochemistry, Karadeniz Technical University, School of Medicine, Trabzon, Turkey
    • ,
  • Cagdas Bayram

      Affiliations

    • Department of Obstetric and Gynecology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey
    • ,
  • Utku Ucar

      Affiliations

    • Department of Biochemistry, Karadeniz Technical University, School of Medicine, Trabzon, Turkey
    • ,
  • Mehmet Ozeren

      Affiliations

    • Department of Obstetric and Gynecology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey

Received 13 November 2008 ,Revised 18 December 2008 ,Accepted 18 May 2009.

References 

  1. Bar-Or D, Curtis G, Rao N, et al. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. European Journal of Biochemistry. 2001;268:42–47
  2. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. Journal of the Society for Gynecologic Investigation. 2001;8:S40–S42
  3. Borderie D, Allanore Y, Meune C, et al. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clinical Chemistry. 2004;50:2190–2193
  4. Dinger Y, Akcay T, Erdem T, et al. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scandinavian Journal of Clinical and Laboratory Investigation. 2005;65:721–728
  5. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Seminars in Reproductive Medicine. 2008;26:39–44
  6. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?. Human Reproduction. 2006;21:104–108
  7. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews. 2005;26:251–282
  8. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertility and Sterility. 2003;80:123–127
  9. Gleicher N, Barad D. An evolutionary concept of polycystic ovarian disease: does evolution favour reproductive success over survival?. Reproductive BioMedicine Online. 2006;12:587–589
  10. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2006;91:336–340
  11. Gunduz A, Mentese A, Turedi S, et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia. Emergency Medicine Journal. 2008;25:351–353
  12. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Annals of Internal Medicine. 1999;131:376–386
  13. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia?. International Journal of Cardiology. 2006;108:410–411
  14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  15. Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism. 2008;57:961–965
  16. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–697
  17. Oktem M, Ebru Ozcimen E, Uckuyu A, et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertility and Sterility. 2008;91:2545–2550
  18. Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertility and Sterility. 2006;86(Suppl. 1):S20–S21
  19. Palacio JR, Iborra A, Ulcova-Gallova Z, et al. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clinical and Experimental Immunology. 2006;144:217–222
  20. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus – preliminary report. Disease Markers. 2008;24:311–317
  21. Sinha MK, Roy D, Gaze DC, et al. Role of ‘ischemia modified albumin’, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emergency Medicine Journal. 2004;21:29–34
  22. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 19, 41–47.
  23. Turedi S, Gunduz A, Mentese A, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respiratory Research. 2008;9:49
  24. Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. American Journal of Emergency Medicine. 2007;25:770–773
  25. Uchida Y, Ohba K, Yoshioka T, et al. Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway. The Journal of Biological Chemistry. 2004;279:4075–4083
  26. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecologic and Obstetric Investigation. 2008;65:233–239
  27. Xi L, Taher M, Yin C, Salloum F, Kukreja RC. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. American Journal of Physiology, Heart and Circulatory Physiology. 2004;287:H2369–H2375
  28. Yarali H, Yildirir A, Aybar F, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertility and Sterility. 2001;76:511–516

 Suleyman Guven obtained his medical degree and specialization in Obstetrics and Gynecology from Hacettepe University, School of Medicine, Ankara, Turkey. He has been a member of the academic staff (assistant professor) of Karadeniz Technical University, Faculty of Medicine, Department of Obstetrics and Gynecology since 2006. He is author or co-author of 49 published papers and one international book chapter. His special interests are polycystic ovary syndrome and endoscopic surgery.Dr Suleyman Guven

PII: S1472-6483(09)00018-2

doi: 10.1016/j.rbmo.2009.05.012

Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 493-500 , October 2009

Article Tools

* Image Usage & Resolution